Forbes featured AMR Action Fund CEO Henry Skinner in its “Investor’s Hot Take” column, which asks investors to weigh in on emerging trends in technology and innovation. Skinner discussed the limitations of AI in antibiotic development, advances in pathogen surveillance, and China’s growing role as a global hub for biopharmaceutical innovation.
On AI, Skinner cautioned that while the technology is accelerating antibiotic discovery, it cannot address the underlying market failures that have driven investment and expertise away from later-stage antibiotic development. He also highlighted the emergence of continuous pathogen surveillance systems and the need to begin considering how medicines increasingly developed in China will reach patients around the world.
Read the full interview here.